NewsRoom Articles - BioMedWire (BMW)

FridayJul 31, 2026 10:00 am

Climate Change is Accelerating the Spread of Infectious Diseases, Experts Warn

Scientists and public health experts are warning that climate change is accelerating the rate at which infectious diseases spread, and policymakers don’t seem to be taking this threat as seriously as they should. A sobering example is the 14 million cases of dengue fever that were recorded globally in 2024. This figure was double what had been documented in 2023, 7 million cases. A major contributor to this spike was the El Niño weather that occurred around that time. That spike in dengue cases was alarming, and it was also a warning sign that as the planet continued warming up, many more such massive outbreaks of infectious diseases…

ThursdayJul 30, 2026 10:00 am

Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment

Glioblastoma multiforme (GBM) is the deadliest type of brain cancer and patients usually die within 15 months from the time they are diagnosed with the malignancy. Existing treatments like surgery, chemotherapy and radiotherapy aren’t effective in halting the progression of this disease. Now, a new study shows that an experimental therapy containing vitamin B12 could halt GBM in its tracks. The study was conducted by a team at the Taussig Cancer Center of the Cleveland Clinic Foundation together with Nitric Oxide Services LLC. The researchers investigated a vitamin B12 compound called NO-Cbl (nitrosylcobalamin). This modified type of vitamin B12 releases nitric oxide. The purpose of the preclinical study was to look into whether this compound could…

WednesdayJul 29, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. Recent regulatory feedback from Germany's Paul-Ehrlich-Institute has provided additional clarity for development of the company's lead BiTAC(R)-TCE program. Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics…

TuesdayJul 28, 2026 11:15 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization. Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair. GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes. Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address…

TuesdayJul 28, 2026 10:00 am

Researchers Plan to Investigate Role of Autoantibodies in Cancer Risk, Immune Response

For a long time, scientists have wondered why many individuals that have several risk factors linked to cancer development never develop the disease while some people without any of these risk factors go on to develop cancer. A team of researchers strongly thinks autoantibodies could provide major insights into why this happens, and they are planning to conduct studies aimed at understanding how autoantibodies influence the likelihood of cancer development, the progression of the disease, and how immune function is shaped in response to cancer development. The team, led by Doctor Laurent Casanova, has done extensive work on autoantibodies, immune proteins that bind to different molecules like the proteins found on viruses, bacteria and other pathogens. These…

TuesdayJul 28, 2026 9:00 am

Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine, clinical support, and fulfilment RxCompoundStore and Mister Meds are licensed compounding pharmacies, which produce custom medications that are supplied wholesale to independent clinics and directly to consumers through ETST’s other subsidiary, Peaks Curative LLC The subsidiaries create a dual-market operation that reduces reliance on one market segment and continues to contribute to Earth Science Tech’s cash-flow-driven and dilution-free growth In fiscal year 2026, Earth Science Tech reduced its total liabilities and increased its total assets, resulting in a net increase…

MondayJul 27, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology's most persistent development challenges. Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support…

FridayJul 24, 2026 10:30 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions. Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair. These developments underscore the company's broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies. Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply…

FridayJul 24, 2026 10:00 am

Health Insurance Keeps 25% of US Employees Locked in Their Jobs

According to the findings of a recent poll conducted by Gallup and West Health, almost a quarter of employees within the U.S., or about 23 million individuals, remain doing jobs they would have otherwise left. They stay due to their desire to retain their health insurance. The data shows that “job lock” has been growing over the years and this latest survey indicates an increase of 8% from the number of people who reported being stuck in their jobs due to health insurance concerns in 2021. This comes as costs of healthcare are increasing to levels that are widely considered a crisis that needs to be fixed to tame rising medical…

ThursdayJul 23, 2026 10:30 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Climate Change is Accelerating the Spread of Infectious Diseases, Experts Warn

Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Researchers Plan to Investigate Role of Autoantibodies in Cancer Risk, Immune Response

Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Health Insurance Keeps 25% of US Employees Locked in Their Jobs

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Precision Oncology as Biomarker-Driven Cancer Gains Momentum

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search